跳至主要内容
临床试验/NCT01826760
NCT01826760已完成不适用

Study of 3-month Mortality Risk of Acute-on-chronic Hepatitis B Liver Failure Using Artificial Neural Network

Wenzhou Medical University1 个研究点 分布在 1 个国家目标入组 583 人开始时间: 2010年4月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
583
试验地点
1
主要终点
Living status

研究概览

简要总结

This study was to predict 3-month mortality risk of acute-on-chronic hepatitis B liver failure (ACHBLF) on an individual patient level using artificial neural network (ANN) system. The area under the curve of receiver operating characteristic (AUROC) were calculated for ANN and MELD-based scoring systems to evaluate the performances of the ANN prediction.

详细描述

Hepatitis B virus (HBV) is a major human pathogen which causes high morbidity and mortality worldwide. HBV is one of the leading causes for rapid deterioration of liver function, which is a serious condition termed as "acute-on-chronic liver failure (ACLF)" with high mortality. There is a high prevalence of HBV in Asian developing countries where acute-on-chronic hepatitis B liver failure (ACHBLF) accounts for more than 70% of ACLF and almost 120, 000 patients died of ACHBLF each year. The transplantation of liver is the basic and strong effective therapeutic option for ACHBLF patients. However, liver transplantation is difficult to be extensively applied due to the shortage of liver donors and other socioeconomic problems. Thus, an early predictive model, which is objective, reasonable and accurate, is necessary for severity discrimination and organ allocation to decrease the mortality of ACHBLF.

MELD-based scoring systems still failed to predict the mortality of a considerable proportion of patients and their predictive accuracy was not satisfying enough.

The ANN is a novel computer model inspired by the working of human brain. It can build nonlinear statistical models to deal with the complex biological systems. In the recent years, ANN models have been introduced in clinical medicine for clinical validations, including predicting the hepatocellular carcinoma patients' disease-free survival and preoperative tumor grade, predicting the mortality of patients with end-stage liver disease and identifying the risk of prostate carcinoma.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Cross Sectional

入排标准

年龄范围
19 Years 至 87 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Acute hepatic insult manifesting as jaundice and coagulopathy
  • Complicated within 4 weeks by ascites
  • And/or encephalopathy in a patient with chronic HBV infection

排除标准

  • Patients with evidence of non-B hepatitis virus
  • alcohol abuse leads to liver failure
  • autoimmune leads to liver failure
  • oxic or other causes that might lead to liver failure
  • past or current hepatocellular carcinoma
  • liver transplantation
  • serious diseases in other organ systems

结局指标

主要结局

Living status

时间窗: Up to 08 months

The routine therapy of patients were same, including absolute bed rest, energy supplements and vitamins, intravenous drop infusion albumin, maintenance water, electrolyte and acid-base equilibrium, and prevention and treatment complications, etc. The start date of the follow-up was the date of the diagnosis of ACHBLF. In this study, patients receiving liver transplantation within 3 months were considered as death. All patients with ACHBLF were followed up for at least 3 months and the outcome (death or survival) of corresponding patient was recorded.

Calculating MELD-based Scoring Systems

时间窗: Up to 02 months

MELD score (R = 9.57 × ln (creatinine (mg/dL)) + 3.78×ln (bilirubin (mg/dL)) + 11.2×ln (INR) + 6.43) was used to measure the mortality risk in patients with end-stage liver disease. Given the lack of donors, MELD was used as organ allocation tool to increase graft success rate and patient survival rates, which was generally accepted. Recently, some adjustments were added to the original MELD formula to overcome limitations of MELD score. Published data suggested that MELD-Na (R = MELD + 1.59 × (135 - serum sodium (mmol/L))) might improve the prognostic accuracy \[5\]. Furthermore, several other scoring systems such as MELDNa (R = MELD - serum sodium (mmol/L) - (0.025 × MELD × (140 - serum sodium (mmol/L))) + 140), MESO (R = (MELD/serum sodium (mmol/L)) × 100), iMELD (R = MELD + (age(year) × 0.3) - (0.7 × serum sodium (mmol/L)) + 100)), etc had been described for predicting the mortality of end-stage liver disease accurately.

Construction of ANN

时间窗: Up to 01 months

ANN can mimic a biological neural system both structurally and functionally. It consists of a set of highly complex, interconnected processing units (neurons) linked with weighted connections, and include an input layer, an output layer and one or more hidden layers. The input layer contains neurons which receive the data available for the analysis (e.g. various clinical, demographic or laboratory data) and the output layer contains neurons which export different predictive outcomes (e.g. clinical diagnosis or prognosis). The hidden layers are used to allow complex relations between the input and output neurons to evolve.In this study, we built ANN by using a graphical neural network development tool NeuroSolution V5.05 (Neurodimension, Florida, United State).

次要结局

  • Statistical Analysis(Up to 02 months)
  • Laboratory Tests(Up to 07 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ming-Hua Zheng

Attending physician

Wenzhou Medical University

研究点 (1)

Loading locations...

相似试验